Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target reduced by equities researchers at Bank of America from $6.00 to $5.00 in a report released on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 56.99% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Finally, Piper Sandler reduced their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Perspective Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $11.56.

Perspective Therapeutics Stock Up 2.7%

CATX stock traded up $0.09 on Friday, reaching $3.19. 588,403 shares of the company traded hands, compared to its average volume of 2,325,881. The firm has a fifty day simple moving average of $3.08 and a 200-day simple moving average of $3.94. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 44.22%. On average, research analysts forecast that Perspective Therapeutics will post -1.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Portland Investment Counsel Inc. purchased a new stake in Perspective Therapeutics during the second quarter valued at $852,000. Bank of New York Mellon Corp bought a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at about $1,015,000. Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 127.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock valued at $225,000 after purchasing an additional 37,000 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $1,581,000. Finally, Avidity Partners Management LP increased its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets raised its 2026 loss estimates: Analyst K. Dolliver now expects a loss of $0.25 per share for the third quarter, $0.26 for the fourth quarter and $0.99 for full-year 2026, compared with previous estimates of $0.32, $0.36 and $1.23, respectively. Smaller projected losses may signal improved expectations for operating performance and could support CATX shares.
• Neutral Sentiment: Losses are still expected through 2027. Brookline forecasts quarterly losses of $0.26, $0.27, $0.30 and $0.32 for the first four quarters of 2027, totaling a projected $1.14 loss for the year. The estimates highlight that Perspective Therapeutics remains an early-stage, loss-making biotechnology company, with future results dependent on clinical and commercial progress.
• Negative Sentiment: Piper Sandler lowered its expectations for the stock price, indicating a less favorable near-term view of CATX’s valuation. The available report does not provide the revised target or the specific reasons for the change. Piper Sandler Has Lowered Expectations for Perspective Therapeutics Stock Price

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.